NYSE: CBT · Specialty Chemicals
Cabot (CBT) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Cabot (CBT) at $78.89 a share. The stock last closed at $70.92, which puts the model's fair value 11.2% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Cabot Corp.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $77.17 to $78.89 (+2.2%). The model's quality adjustment to the peer multiple moved, lifting the fair value: most of the move.
What the model makes of itThe price of $70.92 is 11.2% below it: Fairly valued, on a high evidence grade.
What's nextNext report on 2 Feb 2027. Options prices imply a move of about 11% either way over the next month. On the model's Quality at a Discount list since 6 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give CBT?
The calibrated range for CBT over 63 trading days is $62.58 to $80.88. It sits around the last close, and its width comes from the volatility that CBT's own options imply (38% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $62.45 to $97.39. In 63% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through two segments, Reinforcement Materials and Performance Chemicals.
Faircurve's model put the fair value of Cabot Corp. (CBT) at $78.89 a share on 14 Nov 2026. That is up from $77.17 on the previous run, on 7 Nov 2026, a move of +2.2%. The reason, in the model's own words: the model's quality adjustment to the peer multiple moved, lifting the fair value, and that was most of the move. The calibrated range over 63 trading days is $62.58 to $80.88. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices, using 8,038 past valuations refreshed on 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Cabot scores 71 out of 100 on overall quality against comparable companies, a composite of six quality factors. Profitability stands out most, at 100, with ROIC of 11.4% against a peer median of 5.0%. The balance sheet scores 79, with net debt to EBITDA of 1.43x against a peer median of 3.62x. Capital discipline is the lowest factor, at 42, with net buybacks to market value of 2.7% against a peer median of 1.3%. The model compares Cabot with Ashland Inc. (ASH), Avient Corporation (AVNT), Hawkins, Inc. (HWKN), Sensient Technologies Corporation (SXT), Quaker Houghton (KWR), H.B. Fuller Company (FUL) and Balchem Corp (BCPC).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does CBT report earnings, and how has the stock reacted?
Cabot's next earnings report is scheduled for 2 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 8.8% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. CBT's 30 day implied volatility works out to about 10.9% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CBT's last 8 reports, ignoring direction, was 7.5%.
What the options market has priced for a month's move in CBT
How does CBT score on business quality?
Cabot's overall quality score is 71 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 11.4%ROIC | 5.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 59 | 1.00xFCF / net income | 1.21x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 58 | 0.8%Revenue growth, trailing | -0.6% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 42 | 2.7%Net buybacks / market value | 1.3% |
| Balance sheetNet debt to EBITDA and interest coverage. | 79 | 1.43xNet debt / EBITDA | 3.62x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 50 | 2.3 ptsEBITDA margin downside volatility, 5y | 2.5 pts |
How does CBT compare with similar companies?
The companies in specialty chemicals closest to Cabot in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ASH Ashland Inc. | $75.57 | $70.99 | -6.1% | Fairly valued |
| AVNT Avient Corporation | $43.97 | $42.18 | -4.1% | Fairly valued |
| HWKN Hawkins, Inc. | $148.66 | $136.46 | -8.2% | Fairly valued |
| WDFC WD-40 Company | $226.01 | $208.49 | -7.8% | Low evidence grade |
| SXT Sensient Technologies Corporation | $114.59 | $109.66 | -4.3% | Fairly valued |
| KWR Quaker Houghton | $152.07 | $131.10 | -13.8% | Fairly valued |
| FUL H.B. Fuller Company | $49.00 | $54.04 | +10.3% | Fairly valued |
| BCPC Balchem Corp | $171.48 | $160.63 | -6.3% | Fairly valued |
What the comparable companies' multiples alone would give for CBT, the peer-implied price, is $100.59 a share on this run. The fair value weighs that against the company's own multiple.
Cabot at a glance
Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through two segments, Reinforcement Materials and Performance Chemicals.
- Market value
- $3.7B
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Revenue expected, next twelve months
- $3.9B
- Consensus revenue growth, next fiscal year
- +3.0%
- Analysts with estimates
- 3
- Beta to the US market
- 0.38
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. CBT was among them.
How the fair value is worked out: the model prices Cabot on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for CBT was $77.17. As of 14 Nov 2026 it is $78.89, a change of +2.2%. The model's quality adjustment to the peer multiple moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Cabot's valuation
Is Cabot stock undervalued or overvalued?
On Faircurve's model, CBT reads as Fairly valued as of 14 Nov 2026. The model's fair value is $78.89 a share against a last close of $70.92, a gap of +11.2%.
What is CBT's fair value?
$78.89 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $62.45 to $97.39.
What price range does the model give CBT?
$62.58 to $80.88 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Cabot report earnings next?
The next report is scheduled for 2 Feb 2027. Companies can move their dates.
How much has CBT moved on past earnings reports?
Across its last 8 reports the median two session move was 7.5%, ignoring direction. The largest was +11.2% around the report of 4 Aug 2025.
How confident is the model in this valuation?
The model's evidence grade for CBT is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on CBT
The model has an idea open on CBT under Quality at a Discount since 6 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CBT with their outcomes. A free account is enough.